MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging

Elias, Jorge; Altun, Ersan; Zacks, Steven; Armao, Diane; Woosley, John T.; Semelka, Richard C.

doi:10.1016/j.mri.2009.02.002

Cited by 26 publications

(21 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elias et al evaluated the correlation between MRI findings and Mayo End-Stage Liver Disease (MELD) score (26). Their report showed that there was no statistically significant correlation between the MRI findings and MELD score.…”

Section: Discussionmentioning

confidence: 99%

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, proton MR spectroscopy is evolving to detect not only the full spectrum of steatosis but also other features such as the degree of fibrosis [13,78] . Transabdominal ultrasonography is the most common imaging technique to diagnose hepatic steatosis due to its widespread availability, noninvasiveness and low cost [76] .…”

Section: Clinical Features Of Nafldmentioning

confidence: 99%

Non-alcoholic fatty liver disease: The diagnosis and management

El-Kader

Ashmawy

2015

WJH

319

253

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is now the most frequent chronic liver disease that occurs across all age groups and is recognized to occur in 14%-30% of the general population, representing a serious and growing clinical problem due to the growing prevalence of obesity and overweight. Histologically, it resembles alcoholic liver injury but occurs in patients who deny significant alcohol consumption. NAFLD encompasses a spectrum of conditions, ranging from benign hepatocellular steatosis to inflammatory nonalcoholic steatohepatitis, fibrosis, and cirrhosis. The majority of hepatocellular lipids are stored as triglycerides, but other lipid metabolites, such as free fatty acids, cholesterol, and phospholipids, may also be present and play a role in disease progression. NAFLD is associated with obesity and insulin resistance and is considered the hepatic manifestation of the metabolic syndrome, a combination of medical conditions including type 2 diabetes mellitus, hypertension, hyperlipidemia, and visceral adiposity. Confirmation of the diagnosis of NAFLD can usually be achieved by imaging studies; however, staging the disease requires a liver biopsy. Current treatment relies on weight loss and exercise, although various insulin-sensitizing agents, antioxidants and medications appear promising. The aim of this review is to highlight the current information regarding epidemiology, diagnosis, and management of NAFLD as well as new information about pathogenesis, diagnosis and management of this disease.

show abstract

“…Tissue sections were stained with hematoxylin and eosin (H&E) or Azan, and examined under a light microscope using the DMD108 (Leica, Wetzlar, Germany). Steatosis, inflammation, hepatocyte ballooning [19], macrovesicular steatosis [20], and fibrosis [21] were numbered according to the following classifications: (1) grade of steatosis: 0, none; 1, mild (5-33% of parenchymal involvement by steatosis); 2, moderate (33-66%); 3, severe ([66%); (2) lobular inflammations: 0, none; 1, mild; 2, moderate; 3, severe; (3) hepatocyte ballooning: 0, none; 1, few ballooned cells; 2, many cell-prominent ballooning; (4) macrovesicular steatosis: same as steatosis scoring; and (5) fibrosis stage: 1, zone 3 perisinusoidal/pericellular fibrosis; 2, zone 3 perisinusoidal/pericellular fibrosis with focal or extensive periportal fibrosis; 3, zone 3 perisinusoidal/pericellular fibrosis and portal fibrosis with focal or extensive bridging fibrosis; 4, cirrhosis. Then, the NAFLD activity scores (NAS) were calculated according to the NASH Clinical Research Network scoring system [19], which has been applied to highfat feeding rats [20].…”

Section: Histopathological Analysismentioning

confidence: 99%

Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr

Kitamori

Naito

Tamada

et al. 2011

Environ Health Prev Med

View full text Add to dashboard Cite

Objectives Patients with nonalcoholic fatty liver disease are increasing worldwide, and preventive measures are an urgent need and primary concern today. Aim This study aimed to develop and clarify the usefulness of the SHRSP5/Dmcr rat, derived from a stroke-prone spontaneously hypertensive rat, as a novel animal model for time-course analysis of steatohepatitis and the severe fibrosis progression often observed in the disease. Methods Ten-week-old male SHRSP5/Dmcr rats were divided into six groups: half were fed a high-fat and highcholesterol-containing diet (HFC diet), and the others the control, stroke-prone (SP) diet for 2, 8, and 14 weeks.

show abstract

MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging

Cited by 26 publications

References 49 publications

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

Non-alcoholic fatty liver disease: The diagnosis and management

Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr

Contact Info

Product

Resources

About